Safety and Weight Reduction of Sibutramine in the Treatment of Thai Obese and Overweight Subjects

NCT00234988 Phase 4 COMPLETED

The purpose of the study is to determine the safety and weight loss when sibutramine is used in overweight and obese subjects.

Details

Lead sponsor	Abbott
Phase	Phase 4
Status	COMPLETED
Enrolment	93
Start date	2004-06

Conditions

• Obesity

Interventions

• sibutramine hydochloride monohydrate

Primary outcomes

• Weight loss — 48 weeks
• Safety parameters — 48 weeks

Countries

United States